Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

•Vaccine breakthrough of father and son living in separate households•Delta (B.1.617.2) variant vaccine breakthrough cases•One case was severe enough to lead to hospitalization•Despite high titer of anti-spike IgG, bamlanivimab/etesevimab provided resolution of symptoms We present two Delta (B.1.617...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2021-09, Vol.110, p.232-234
Main Authors: Connor, Bradley A, Couto-Rodriguez, Mara, Barrows, Joseph E, Gardner, Morgan, Rogova, Marina, O'Hara, Niamh B., Nagy-Szakal, Dorottya
Format: Article
Language:English
Subjects:
B.1.617.2
bamlanivimab/etesevimab
breakthrough
Case Report
COVID-19
Delta variant
monoclonal antibody therapy
SARS-CoV-2
variant of concern
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Vaccine breakthrough of father and son living in separate households•Delta (B.1.617.2) variant vaccine breakthrough cases•One case was severe enough to lead to hospitalization•Despite high titer of anti-spike IgG, bamlanivimab/etesevimab provided resolution of symptoms We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2021.07.029